Methylphenidate in Myotonic Dystrophy Type 1

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether methylphenidate is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laval University
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• adults

• Epworth score ≥ 10

• Diagnosis of myotonic dystrophy type 1

Exclusion Criteria:

• hypersensibility to methylphenidate

• Pregnancy

• Patients who receive drugs that interfere with methylphenidate

• Cognitive impairment

• Sleep apnea